Meeting Announcement: US FDA Advisory Committee to Review Ferring’s NOCDURNA

The US FDA has scheduled an Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting for  Monday, January 12, 2014 to discuss the safety and efficacy of new drug application (NDA) 022517, proposed trade name NOCDURNA (established name: desmopressin), orally disintegrating sublingual tablets submitted by Ferring Pharmaceuticals, Inc. The proposed indication is treatment of nocturia due to nocturnal polyuria in adults who awaken two or more times each night to void.

See the FDA Announcement